COMPANY RELEASE
Resolutions of
Remuneration policy
The Board of Directors
The Extraordinary General Meeting resolved that the Board of Directors consists of four members.
It was resolved that the monthly remuneration of the New Board Member
Issue of special rights
The Extraordinary General Meeting resolved to issue special rights, entitling to shares as referred to in Chapter 10 Section 1 of the Finnish Limited Liability Companies Act to the New Board Member, on the following terms:
i. The total number of options rights to be issued is at most 59,726;
ii. The option rights entitle the New Board Member to subscribe for a maximum of 59,726 shares;
iii. The option rights are issued without payment;
iv. The subscription right may not be transferred;
v. The subscription period of the option rights commences immediately and is in force until
vi. Each option right entitles the option holder to subscribe for new ordinary shares of the company;
vii. The subscription period for shares based on the option rights shall commence from the registration of the stock options to the
viii. The subscription price of the shares subscribed with the option is
ix. The condition for approving the subscription of the options is that the party entitled to subscribe for the options, sign an option agreement.
The detailed terms and conditions of the options rights have been published on
The stock options are issued in order to commit the New Board Member of the company. Therefore, there is a weighty financial reason from the company's point of view to issue stock options as provided in Chapter 10, Section 1 of the Finnish Limited Liability Companies Act.
The aggregated theoretical market value of the issued stock options is estimated at
The minutes of the General Meeting will be available on the website of
Decision by the Board of Directors on the composition of its
The Board of Directors elected
Board of Directors
For further information, please contact:
peter.hanninen@nanoform.com / +358 50 353 0408
For investor relations queries, please contact:
hvh@nanoform.com / +46 7686 650 11
Certified Adviser:
About Nanoform
Nanoform is an innovative nanoparticle medicine enabling company. Nanoform works together with pharma and biotech partners globally to reduce attrition in clinical trials and enhance their molecules' formulation performance through its nanoforming services. The Company's patented and scalable Controlled Expansion of Supercritical Solutions (CESS[®)] technology produces nanoformed API particles as small as 10nm. This enables poorly soluble molecules in the pharmaceutical pipeline to progress into clinical development by increasing their rate of dissolution and by improving their bioavailability. Nanoform's unique technology provides novel opportunities in many value-enhancing drug delivery applications.
For more information please visit http://www.nanoform.com
https://news.cision.com/nanoform/r/resolutions-of-nanoform-finland-plc-s-extraordinary-general-meeting-and-board-of-directors-on-septem,c3186702
(c) 2020 Cision. All rights reserved., source